A Study in Healthy Volunteers Comparing Two Different Liquid Formulations of Solifenacin With Each Other and With the Tablet Formulation

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Astellas Pharma Inc
ClinicalTrials.gov Identifier:
NCT01406158
First received: July 14, 2011
Last updated: August 23, 2011
Last verified: August 2011

July 14, 2011
August 23, 2011
May 2011
July 2011   (final data collection date for primary outcome measure)
Pharmacokinetic assessment of AUC and maximum concentration (Cmax) through the analysis of blood samples [ Time Frame: Up to Day 11 ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01406158 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Study in Healthy Volunteers Comparing Two Different Liquid Formulations of Solifenacin With Each Other and With the Tablet Formulation
A Phase 1, Open-Label, Randomized, Single Dose, 3-Way Crossover Study to Assess the Relative Bioavailability of Solifenacin Liquid Suspension 10 mg (Formulation B) Versus Solifenacin Liquid Suspension 10 mg (Formulation A) and to Assess the Relative Bioavailability of Solifenacin Liquid Suspension 10 mg (Formulation A and B) Versus the VESIcare (Solifenacin Succinate) 10 mg Tablet in Healthy Volunteers

A study in healthy volunteers comparing two different liquid formulations of solifenacin with each other and with the tablet formulation.

Subjects will be randomized to one of six treatment sequences. The treatments will be separated by a minimum of 13 days between dosing.

Study drug will be administered after an overnight fast, and food will be restricted for an additional four hours after dosing. Except for the water provided with dosing, water will be restricted only during the hour before and the hour after dosing.

Subjects will stay at the study site for the first three days of each treatment period. Subjects will return to the study center each morning at the same time of the day for Days 4 through 11 of each study period for the pharmacokinetic blood draw and vital signs. Subjects will be in the study for at least 40 days.

Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Bio-availability Study
Intervention Model: Crossover Assignment
Masking: Open Label
  • Pharmacokinetics of Solifenacin Succinate
  • Healthy Volunteers
  • Drug: Solifenacin Succinate Formulation A
    oral suspension
    Other Name: YM905
  • Drug: Solifenacin Succinate Formulation B
    oral suspension
    Other Name: YM905
  • Drug: Solifenacin Succinate
    oral tablet
    Other Names:
    • VESIcare
    • YM905
  • Experimental: Treatment A
    Intervention: Drug: Solifenacin Succinate Formulation A
  • Experimental: Treatment B
    Intervention: Drug: Solifenacin Succinate Formulation B
  • Experimental: Treatment T
    Intervention: Drug: Solifenacin Succinate
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
24
July 2011
July 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subject weighs at least 45 kg, and has a body mass index of 18 to 32 kg/m2
  • Subject has a normal 12-lead electrocardiogram (ECG)
  • Subject, if female, must be at least 2 years postmenopausal, surgically sterile, or practicing effective birth control, and is not pregnant or lactating
  • Subject has good venous access

Exclusion Criteria:

  • The subject has a history of any clinically significant disease or malignancy with the exception of non-melanoma skin cancer
  • The subject has a history of or currently has evidence of urinary retention, gastric retention, or uncontrolled narrow-angle-glaucoma
  • The subject has a history of unexplained syncope, cardiac arrest, unexplained cardiac arrhythmia or torsade de pointes, structural heart disease, or family history of Long QT syndrome (suggested by sudden death of a close relative at a young age due to possible or probable cardiac causes)
  • The subject has a known hypersensitivity to VESIcare® or any of the excipients in the formulations, or the subject has a history of severe allergic or anaphylactic reactions
  • The subject has a history of consuming more than 15 units of alcoholic beverages per week, or has a history of alcoholism or substance abuse within the past two years prior to screening (Note: one unit = 12 ounces of beer, 4 ounces of wine, or 1 ounce of spirits)
  • The subject has used tobacco containing products or nicotine containing products within past six months
  • The subject has a supine mean systolic blood pressure < 90 or > 160 mmHg and a mean diastolic blood pressure < 50 or > 90 mmHg, or pulse rate < 40 or >100 beats per minute
  • The subject is known to be positive for human immunodeficiency virus antibody
  • The subject has a positive test for hepatitis C antibody or hepatitis B antigen
  • The subject's laboratory test results are outside the normal limits and considered to be clinically significant
  • The subject has had treatment with prescription or non-prescription drugs, including complementary and alternative medicines or over-the-counter medications, with the exception of hormonal contraceptives, hormone replacement therapy, and occasional use of acetaminophen within 14 days prior to inclusion into the study
  • The subject anticipates an inability to abstain from alcohol or caffeine use throughout the duration of the study or from grapefruit, Seville oranges, star fruit, or any products containing these items from throughout the duration of the study
  • The subject has received an experimental agent within past 30 days or ten half-lives, whichever is longer
  • The subject has had any significant blood loss
  • The subject has any clinically significant history of gastrointestinal symptoms such as nausea, abdominal discomfort or upset, or heartburn in the four weeks prior to clinic admission, or a history of any gastrointestinal surgery except for appendectomy or cholecystectomy
Both
18 Years to 55 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01406158
905-CL-080
No
Astellas Pharma Inc
Astellas Pharma Inc
Not Provided
Study Director: Medical Director Astellas Pharma Global Development
Astellas Pharma Inc
August 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP